New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2013
13:40 EDTMDVN, JNJJ&J results imply strength for Medivation drug, says William Blair
William Blair believes Johnson & Johnson's (JNJ) Q4 results this morning, which included the trending down of sales for its metastatic prostate cancer drug Zytiga, implies strength for Medivation's (MDVN) Xtandi. The firm believes J&J's decreased sales of Zytiga in Q4 were largely due to competitor Xtandi's U.S. launch in September. William Blair keeps an Outperform rating on shares of Medivation, which are trading up 4% to $57.10 after J&J's results.
News For MDVN;JNJ From The Last 14 Days
Check below for free stories on MDVN;JNJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
10:00 EDTMDVNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:47 EDTMDVNMedivation upgraded to Buy at Canaccord
As reported previously, Canaccord upgraded Medivation to Buy from Hold citing the pre-chemotherapy opportunity and meaningful incremental share gains of its Xtandi drug. Canaccord raised its price target on Medivation to $132 from $60.
06:13 EDTMDVNMedivation upgraded to Buy from Hold at Canaccord
Subscribe for More Information
September 17, 2014
08:36 EDTJNJJanssen-Cilag announces results from post-hoc canagliflozin analysis
Subscribe for More Information
08:12 EDTJNJJanssen-Cilag announces results from Phase 3 Invokana trial
Subscribe for More Information
September 16, 2014
07:31 EDTJNJEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
September 15, 2014
07:27 EDTJNJIBC Life Sciences to hold a conference
Subscribe for More Information
September 11, 2014
07:50 EDTMDVNPotential of Medivation Xtandi underappreciated, says Bernstein
Subscribe for More Information
07:37 EDTMDVNMedivation to host conference call
Conference call to discuss FDA approval of XTANDIŽ to be held on September 11 at 8:30 am. Webcast Link
07:11 EDTJNJ, MDVNMedivation price target raised to $112 from $89 at Stifel
Subscribe for More Information
September 10, 2014
16:41 EDTMDVNMedivation to resume trading at 4:50 pm ET
Subscribe for More Information
16:26 EDTMDVNMedivation receives $90M milestone payment after FDA approves XTANDI indication
Subscribe for More Information
15:16 EDTMDVNMedivation Xtandi efficacy supplement posted to FDA website
Subscribe for More Information
14:48 EDTMDVNMedivation trading halted, pending news
Subscribe for More Information
10:14 EDTJNJJohnson & Johnson says off to 'very good start' this year
Subscribe for More Information
September 9, 2014
10:10 EDTMDVNOn the Fly: Analyst Upgrade Summary
Subscribe for More Information
08:42 EDTMDVNMedivation upgraded at Bernstein
Subscribe for More Information
06:43 EDTMDVNMedivation upgraded to Outperform from Market Perform at Bernstein
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use